AR101806A1 - Derivados de 1-acetil-4-amino-1,2,3,4-tetrahidroquinolina, composición farmacéutica que los comprende y su uso en el tratamiento de afecciones mediadas por un inhibidor de bromodominio - Google Patents
Derivados de 1-acetil-4-amino-1,2,3,4-tetrahidroquinolina, composición farmacéutica que los comprende y su uso en el tratamiento de afecciones mediadas por un inhibidor de bromodominioInfo
- Publication number
- AR101806A1 AR101806A1 ARP150102888A ARP150102888A AR101806A1 AR 101806 A1 AR101806 A1 AR 101806A1 AR P150102888 A ARP150102888 A AR P150102888A AR P150102888 A ARP150102888 A AR P150102888A AR 101806 A1 AR101806 A1 AR 101806A1
- Authority
- AR
- Argentina
- Prior art keywords
- tetrahydroquinoline
- acetyl
- amino
- carboxamide
- dimethyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- UBTOHKCMZLCVOK-UHFFFAOYSA-N 1-(4-amino-3,4-dihydro-2h-quinolin-1-yl)ethanone Chemical class C1=CC=C2N(C(=O)C)CCC(N)C2=C1 UBTOHKCMZLCVOK-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- KLIMMLWRWOHVRC-UHFFFAOYSA-N 1-acetyl-4-[(5-chloropyrimidin-2-yl)amino]-2,3-dimethyl-N-(oxan-4-yl)-3,4-dihydro-2H-quinoline-6-carboxamide Chemical compound C(C)(=O)N1C(C(C(C2=CC(=CC=C12)C(=O)NC1CCOCC1)NC1=NC=C(C=N1)Cl)C)C KLIMMLWRWOHVRC-UHFFFAOYSA-N 0.000 abstract 1
- CHECKZIEONWGDS-OXBKQFJYSA-N 1-acetyl-4-[(5-chloropyrimidin-2-yl)amino]-N-[(2R)-2-hydroxypropyl]-2,3-dimethyl-3,4-dihydro-2H-quinoline-6-carboxamide Chemical compound C(C)(=O)N1C(C(C(C2=CC(=CC=C12)C(=O)NC[C@@H](C)O)NC1=NC=C(C=N1)Cl)C)C CHECKZIEONWGDS-OXBKQFJYSA-N 0.000 abstract 1
- CHECKZIEONWGDS-PWZWTWNFSA-N 1-acetyl-4-[(5-chloropyrimidin-2-yl)amino]-N-[(2S)-2-hydroxypropyl]-2,3-dimethyl-3,4-dihydro-2H-quinoline-6-carboxamide Chemical compound C(C)(=O)N1C(C(C(C2=CC(=CC=C12)C(=O)NC[C@H](C)O)NC1=NC=C(C=N1)Cl)C)C CHECKZIEONWGDS-PWZWTWNFSA-N 0.000 abstract 1
- SBYRTHHPFJYJJS-UHFFFAOYSA-N 1-acetyl-4-[(5-chloropyrimidin-2-yl)amino]-N-ethyl-2,3-dimethyl-3,4-dihydro-2H-quinoline-6-carboxamide Chemical compound C(C)(=O)N1C(C(C(C2=CC(=CC=C12)C(=O)NCC)NC1=NC=C(C=N1)Cl)C)C SBYRTHHPFJYJJS-UHFFFAOYSA-N 0.000 abstract 1
- OUPJXFZVMIIGSN-UHFFFAOYSA-N 1-acetyl-4-[(5-chloropyrimidin-2-yl)amino]-N-ethyl-2-methyl-3,4-dihydro-2H-quinoline-6-carboxamide Chemical compound C(C)(=O)N1C(CC(C2=CC(=CC=C12)C(=O)NCC)NC1=NC=C(C=N1)Cl)C OUPJXFZVMIIGSN-UHFFFAOYSA-N 0.000 abstract 1
- VCEVKNUAOKRNLK-UHFFFAOYSA-N 1-acetyl-4-[(5-cyanopyrazin-2-yl)amino]-N-ethyl-2,3-dimethyl-3,4-dihydro-2H-quinoline-6-carboxamide Chemical compound C(C)(=O)N1C(C(C(C2=CC(=CC=C12)C(=O)NCC)NC1=NC=C(N=C1)C#N)C)C VCEVKNUAOKRNLK-UHFFFAOYSA-N 0.000 abstract 1
- WBKZYVNBPOBFFD-UHFFFAOYSA-N 1-acetyl-4-[(5-cyanopyridin-2-yl)amino]-2,3-dimethyl-N-(oxan-4-yl)-3,4-dihydro-2H-quinoline-6-carboxamide Chemical compound C(C)(=O)N1C(C(C(C2=CC(=CC=C12)C(=O)NC1CCOCC1)NC1=NC=C(C=C1)C#N)C)C WBKZYVNBPOBFFD-UHFFFAOYSA-N 0.000 abstract 1
- KUYJPPKYVRIQLT-RRMGUTHRSA-N 1-acetyl-4-[(5-cyanopyridin-2-yl)amino]-N-[(2R)-2-hydroxypropyl]-2,3-dimethyl-3,4-dihydro-2H-quinoline-6-carboxamide Chemical compound C(C)(=O)N1C(C(C(C2=CC(=CC=C12)C(=O)NC[C@@H](C)O)NC1=NC=C(C=C1)C#N)C)C KUYJPPKYVRIQLT-RRMGUTHRSA-N 0.000 abstract 1
- KUYJPPKYVRIQLT-CQSZKLFBSA-N 1-acetyl-4-[(5-cyanopyridin-2-yl)amino]-N-[(2S)-2-hydroxypropyl]-2,3-dimethyl-3,4-dihydro-2H-quinoline-6-carboxamide Chemical compound C(C)(=O)N1C(C(C(C2=CC(=CC=C12)C(=O)NC[C@H](C)O)NC1=NC=C(C=C1)C#N)C)C KUYJPPKYVRIQLT-CQSZKLFBSA-N 0.000 abstract 1
- CRQWIJHPFSIEAU-UHFFFAOYSA-N 1-acetyl-4-[(5-cyanopyridin-2-yl)amino]-N-ethyl-2,3-dimethyl-3,4-dihydro-2H-quinoline-6-carboxamide Chemical compound C(C)(=O)N1C(C(C(C2=CC(=CC=C12)C(=O)NCC)NC1=NC=C(C=C1)C#N)C)C CRQWIJHPFSIEAU-UHFFFAOYSA-N 0.000 abstract 1
- BWMZCAOODAMQJS-UHFFFAOYSA-N 1-acetyl-N-ethyl-4-[(5-fluoropyridin-2-yl)amino]-2,3-dimethyl-3,4-dihydro-2H-quinoline-6-carboxamide Chemical compound C(C)(=O)N1C(C(C(C2=CC(=CC=C12)C(=O)NCC)NC1=NC=C(C=C1)F)C)C BWMZCAOODAMQJS-UHFFFAOYSA-N 0.000 abstract 1
- MMWZYGRHUXTRPH-UHFFFAOYSA-N C(C)(=O)N1C(C(C(C2=CC(=CC=C12)C(=O)N)NC1=NC=C(C=C1)C#N)C)C Chemical compound C(C)(=O)N1C(C(C(C2=CC(=CC=C12)C(=O)N)NC1=NC=C(C=C1)C#N)C)C MMWZYGRHUXTRPH-UHFFFAOYSA-N 0.000 abstract 1
- KBVHDAHMPAYMQL-UHFFFAOYSA-N C(C)(=O)N1C(C(C(C2=CC(=CC=C12)C(=O)N)NC1=NC=C(C=N1)Cl)C)C Chemical compound C(C)(=O)N1C(C(C(C2=CC(=CC=C12)C(=O)N)NC1=NC=C(C=N1)Cl)C)C KBVHDAHMPAYMQL-UHFFFAOYSA-N 0.000 abstract 1
- LISWTMMIZRPFAS-UHFFFAOYSA-N C(C)(=O)N1C(C(C(C2=CC(=CC=C12)C(=O)N)NC1=NC=C(N=C1)C#N)C)C Chemical compound C(C)(=O)N1C(C(C(C2=CC(=CC=C12)C(=O)N)NC1=NC=C(N=C1)C#N)C)C LISWTMMIZRPFAS-UHFFFAOYSA-N 0.000 abstract 1
- KNBYFXZNSOENGW-UHFFFAOYSA-N C(C)(=O)N1C(CC(C2=CC(=CC=C12)C(=O)N)NC1=NC=C(C=N1)Cl)C Chemical compound C(C)(=O)N1C(CC(C2=CC(=CC=C12)C(=O)N)NC1=NC=C(C=N1)Cl)C KNBYFXZNSOENGW-UHFFFAOYSA-N 0.000 abstract 1
- 229940125763 bromodomain inhibitor Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos, a composiciones farmacéuticas que contienen tales compuestos y a su uso en terapia de afecciones para las cuales está indicado un inhibidor de bromodominio. Reivindicación 1: Un compuesto seleccionado del grupo que consiste en: 1-acetil-4-((5-cloropirimidin-2-il)amino)-2-metil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopiridin-2-il)amino)-N-etil-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopiridin-2-il)amino)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopiridin-2-il)amino)-2,3-dimetil-N-(tetrahidro-2H-piran-4-il)-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopiridin-2-il)amino)-N-((R)-2-hidroxipropil)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopiridin-2-il)amino)-N-((S)-2-hidroxipropil)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cloropirimidin-2-il)amino)-N-etil-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cloropirimidin-2-il)amino)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cloropirimidin-2-il)amino)-2,3-dimetil-N-(tetrahidro-2H-piran-4-il)-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cloropirimidin-2-il)amino)-N-((S)-2-hidroxipropil)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cloropirimidin-2-il)amino)-N-((R)-2-hidroxipropil)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopirazin-2-il)amino)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cianopirazin-2-il)amino)-N-etil-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-N-etil-4-((5-fluoropiridin-2-il)amino)-2,3-dimetil-1,2,3,4-tetrahidroquinolina-6-carboxamida; 1-acetil-4-((5-cloropirimidin-2-il)amino)-N-etil-2-metil-1,2,3,4-tetrahidroquinolina-6-carboxamida; y@@@1-acetil-4-((5-cianopiridin-2-il)amino)-N-etil-2-metil-1,2,3,4-tetrahidroquinolina-6-carboxamida; o una sal del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049449P | 2014-09-12 | 2014-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101806A1 true AR101806A1 (es) | 2017-01-11 |
Family
ID=54065889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102888A AR101806A1 (es) | 2014-09-12 | 2015-09-10 | Derivados de 1-acetil-4-amino-1,2,3,4-tetrahidroquinolina, composición farmacéutica que los comprende y su uso en el tratamiento de afecciones mediadas por un inhibidor de bromodominio |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US10059699B2 (es) |
| EP (1) | EP3191476B1 (es) |
| JP (1) | JP6531167B2 (es) |
| KR (1) | KR20170054421A (es) |
| CN (1) | CN106687453B (es) |
| AR (1) | AR101806A1 (es) |
| AU (1) | AU2015314184B2 (es) |
| BR (1) | BR112017004580A2 (es) |
| CA (1) | CA2958159A1 (es) |
| CL (1) | CL2017000587A1 (es) |
| CO (1) | CO2017001601A2 (es) |
| CR (1) | CR20170090A (es) |
| CY (1) | CY1121369T1 (es) |
| DK (1) | DK3191476T3 (es) |
| DO (1) | DOP2017000058A (es) |
| EA (1) | EA031679B9 (es) |
| ES (1) | ES2705623T3 (es) |
| HR (1) | HRP20182064T1 (es) |
| HU (1) | HUE041694T2 (es) |
| IL (1) | IL250397A0 (es) |
| LT (1) | LT3191476T (es) |
| MA (1) | MA40366A (es) |
| MX (1) | MX373845B (es) |
| PE (1) | PE20170675A1 (es) |
| PH (1) | PH12017500348A1 (es) |
| PL (1) | PL3191476T3 (es) |
| PT (1) | PT3191476T (es) |
| RS (1) | RS58135B1 (es) |
| SG (1) | SG11201701043UA (es) |
| SI (1) | SI3191476T1 (es) |
| SM (1) | SMT201900019T1 (es) |
| TR (1) | TR201820050T4 (es) |
| TW (1) | TWI686389B (es) |
| UY (1) | UY36292A (es) |
| WO (1) | WO2016038120A1 (es) |
| ZA (1) | ZA201700883B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105026395B (zh) | 2013-03-14 | 2018-07-20 | 勃林格殷格翰国际有限公司 | 取代的氮杂双环酰胺类组织蛋白酶c抑制剂及其药物组合物和制药用途 |
| NZ728684A (en) | 2014-09-12 | 2022-09-30 | Boehringer Ingelheim Int | Spirocyclic inhibitors of cathepsin c |
| WO2018111805A1 (en) * | 2016-12-13 | 2018-06-21 | St. Jude Children's Research Hospital | Tetrahydroquinoline-based bromodomain inhibitors |
| BR112021007982A2 (pt) | 2018-10-30 | 2021-08-03 | Nuvation Bio Inc. | compostos heterocíclicos como inibidores de bet |
| CN114286818B (zh) | 2019-07-02 | 2024-09-20 | 诺维逊生物股份有限公司 | 作为bet抑制剂的杂环化合物 |
| EP4095128A1 (en) | 2021-05-25 | 2022-11-30 | Centre national de la recherche scientifique | Tetrahydroquinoline (thq) coumpounds |
| US12527741B2 (en) | 2021-06-17 | 2026-01-20 | Wisconsin Alumni Research Foundation | Modular dendron micelles for treatment of pulmonary diseases related to fibrosis and viral infection including COVID-19 |
| CN116919963B (zh) * | 2023-07-28 | 2025-09-12 | 浙江大学 | 一种基于水网络策略的溴结构域蛋白4活性化合物的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2415764A4 (en) * | 2009-03-31 | 2012-08-08 | Kowa Co | PROPHYLACTIC AND / OR THERAPEUTIC AGENT AGAINST ANEMIA WITH A TETRAHYDROCHINOLINE COMPOUND AS AN ACTIVE SUBSTANCE |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB201106750D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201106743D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201107325D0 (en) | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| HRP20182179T1 (hr) * | 2013-03-14 | 2019-02-22 | Glaxosmithkline Intellectual Property (No. 2) Limited | 2,3-disupstituirani 1-acil-4-amino-1,2,3,4-tetrahidrokonolin derivati i njihova uporaba kao inhibitora bromodomena |
-
2015
- 2015-09-09 SM SM20190019T patent/SMT201900019T1/it unknown
- 2015-09-09 PT PT15760461T patent/PT3191476T/pt unknown
- 2015-09-09 EP EP15760461.2A patent/EP3191476B1/en active Active
- 2015-09-09 KR KR1020177008675A patent/KR20170054421A/ko not_active Withdrawn
- 2015-09-09 HR HRP20182064TT patent/HRP20182064T1/hr unknown
- 2015-09-09 CA CA2958159A patent/CA2958159A1/en not_active Abandoned
- 2015-09-09 AU AU2015314184A patent/AU2015314184B2/en not_active Ceased
- 2015-09-09 EA EA201790484A patent/EA031679B9/ru not_active IP Right Cessation
- 2015-09-09 RS RS20190001A patent/RS58135B1/sr unknown
- 2015-09-09 DK DK15760461.2T patent/DK3191476T3/en active
- 2015-09-09 HU HUE15760461A patent/HUE041694T2/hu unknown
- 2015-09-09 PE PE2017000388A patent/PE20170675A1/es unknown
- 2015-09-09 TR TR2018/20050T patent/TR201820050T4/tr unknown
- 2015-09-09 BR BR112017004580-0A patent/BR112017004580A2/pt not_active Application Discontinuation
- 2015-09-09 US US15/509,894 patent/US10059699B2/en active Active
- 2015-09-09 CR CR20170090A patent/CR20170090A/es unknown
- 2015-09-09 WO PCT/EP2015/070665 patent/WO2016038120A1/en not_active Ceased
- 2015-09-09 MA MA040366A patent/MA40366A/fr unknown
- 2015-09-09 LT LTEP15760461.2T patent/LT3191476T/lt unknown
- 2015-09-09 PL PL15760461T patent/PL3191476T3/pl unknown
- 2015-09-09 CN CN201580048713.8A patent/CN106687453B/zh not_active Expired - Fee Related
- 2015-09-09 SG SG11201701043UA patent/SG11201701043UA/en unknown
- 2015-09-09 ES ES15760461T patent/ES2705623T3/es active Active
- 2015-09-09 JP JP2017513723A patent/JP6531167B2/ja not_active Expired - Fee Related
- 2015-09-09 SI SI201530529T patent/SI3191476T1/sl unknown
- 2015-09-09 MX MX2017003219A patent/MX373845B/es active IP Right Grant
- 2015-09-10 AR ARP150102888A patent/AR101806A1/es unknown
- 2015-09-10 TW TW104129977A patent/TWI686389B/zh not_active IP Right Cessation
- 2015-09-10 UY UY0001036292A patent/UY36292A/es not_active Application Discontinuation
-
2017
- 2017-02-01 IL IL250397A patent/IL250397A0/en unknown
- 2017-02-03 ZA ZA2017/00883A patent/ZA201700883B/en unknown
- 2017-02-17 CO CONC2017/0001601A patent/CO2017001601A2/es unknown
- 2017-02-27 PH PH12017500348A patent/PH12017500348A1/en unknown
- 2017-03-07 DO DO2017000058A patent/DOP2017000058A/es unknown
- 2017-03-09 CL CL2017000587A patent/CL2017000587A1/es unknown
-
2019
- 2019-01-15 CY CY20191100049T patent/CY1121369T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR101806A1 (es) | Derivados de 1-acetil-4-amino-1,2,3,4-tetrahidroquinolina, composición farmacéutica que los comprende y su uso en el tratamiento de afecciones mediadas por un inhibidor de bromodominio | |
| BR112019006712A2 (pt) | composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo. | |
| CL2018000542A1 (es) | Nuevos derivados de fenoximetilo. | |
| BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| MX2019000451A (es) | Compuesto heterociclico utilizado como inhibidor de fgfr. | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| SV2018005778A (es) | Derivados aromaticos de sulfonamida | |
| MX2020010737A (es) | Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| BR112016016844A2 (pt) | Compostos heterocíclicos | |
| MX379155B (es) | Compuestos que inhiben la proteína mcl-1. | |
| UY36342A (es) | Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos | |
| MX389349B (es) | Derivados de ácido borónico y usos terapéuticos de los mismos. | |
| MX373935B (es) | Compuestos antiproliferativos y métodos de uso de los mismos. | |
| BR112017007460A2 (pt) | inibidores de di-hidropirrolopiridina de ror-gama | |
| BR112017003346B8 (pt) | Derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| NI201600176A (es) | Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer. | |
| AR128459A2 (es) | Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación | |
| BR112017004589A2 (pt) | composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| AR100431A1 (es) | Compuestos de pladienolida piridina y métodos de uso | |
| MX2018009870A (es) | Inhibidores de taf1 para la terapia del cancer. | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |